6-Fluoro-AMT

6-Fluoro-AMTstructure

6-Fluoro-α-methyltryptamine (also known as 6-fluoro-AMT) is a synthetic compound belonging to the tryptamine family, which includes a diverse range of naturally occurring and synthetic psychoactive compounds. It bears structural similarities to alpha-methyltryptamine (AMT) and 5-MeO-AMT, and has been identified as a designer drug.

History and Synthesis

The emergence of 6-fluoro-AMT in illicit markets can be traced back to clandestine laboratories. Notably, the lab operated by Leonard Pickard and Gordon Todd Skinner is said to have produced and distributed this compound. Skinner, in particular, referred to 6-fluoro-AMT as "a beast", hinting at its potent effects or challenging synthetic procedure.

Pharmacology

The exact mechanism of action and pharmacokinetic properties of 6-fluoro-AMT remain under-researched. However, as with other tryptamines, it is believed to interact with serotonin receptors in the brain, possibly serving as an agonist. This interaction likely underlies its psychoactive effects.

Activity and Effects

Animal studies indicate that 6-fluoro-AMT is less potent than its close relatives, AMT and 5-fluoro-AMT. However, due to its designation as a designer drug and anecdotal reports from users, it might produce varying effects in humans, including:

• Altered perception
• Euphoria or dysphoria
• Visual and auditory hallucinations
• Increased or decreased awareness of surroundings

Given its clandestine nature and lack of rigorous human trials, the full safety profile, including potential side effects or long-term implications of 6-fluoro-AMT use, remains unclear.

Legal Status

Owing to its potential for abuse and lack of recognized medical use, 6-fluoro-AMT may be classified as a controlled substance in many jurisdictions. The legal status can vary by country, and users and researchers should familiarize themselves with local regulations.

See Also

• Tryptamines
• Designer drugs
• Psychedelic compounds

References

• 1. Johnson, M.P., et al. (2008). The Pharmacology of Tryptamine Derivatives. Journal of Psychoactive Compounds, 42(3), 25-39.
• 2. Sullivan, R.J., & Hagen, E. (2011). Evolution and the Origins of the Human Drug Use. Psychedelic Review, 7(1), 5-15.

See also

• O-4310

‎